MSS/ MMRp

我们是谁

  • 4 月 5, 2022
    Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate
  • 4 月 5, 2022
    Durvalumab和Tremelimumab联合治疗体细胞高突变复发性实体瘤
  • 4 月 5, 2022
    治疗实体瘤患者的 Pembrolizumab 和重组白细胞介素-12
  • 4 月 5, 2022
    甲苯咪唑作为结肠癌的辅助治疗药物
  • 4 月 5, 2022
    Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC
  • 4 月 5, 2022
    Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
  • 4 月 5, 2022
    利用 CRISPR 基因工程抑制编码细胞内免疫检查点 CISH 基因的肿瘤浸润淋巴细胞治疗转移性胃肠癌的研究
  • 4 月 5, 2022
    Local Immunomodulation After Radiofrequency of Unresectable Colorectal Liver Metastases
  • 4 月 5, 2022
    一项针对晚期实体瘤患者的BMS-986340单药及与Nivolumab联合用药研究
  • 4 月 5, 2022
    Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery